{"gene":"MAGEA3","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":1994,"finding":"MAGE-3 (MAGEA3) gene encodes a tumor antigen recognized by autologous cytolytic T lymphocytes (CTL) on melanoma cell line MZ2-MEL; the antigenic peptide MZ2-D is presented by HLA-A1, and competition experiments with Ala-substituted peptides established that Asp at position 3 and Tyr at position 9 are essential for HLA-A1 binding.","method":"Autologous CTL recognition assay, single alanine-substituted peptide competition experiments","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct peptide-CTL recognition assay with systematic mutagenesis (Ala scanning), foundational paper replicated extensively","pmids":["8113684"],"is_preprint":false},{"year":1994,"finding":"MAGE-3 encodes a second antigenic peptide (FLWGPRALV) presented by HLA-A2 molecules that is recognized by CTL and can be used to stimulate peptide-specific CTL clones that kill HLA-A2+ MAGE-3-expressing tumor cell lines.","method":"HLA-A2 peptide binding assay, in vitro CTL induction with peptide-pulsed lymphoblasts, tumor cell killing assay","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution of peptide-MHC-CTL axis with functional killing readout, replicated by multiple subsequent studies","pmids":["7805731"],"is_preprint":false},{"year":1995,"finding":"The MAGE-3 gene product was identified as a ~48,000 Mr cytoplasmic protein by immunoblotting with a monoclonal antibody generated against recombinant His-tagged MAGE-3; immunohistochemistry confirmed cytoplasmic localization in MAGE-3-expressing cell lines.","method":"Recombinant protein expression, metal chelation purification, monoclonal antibody generation, immunoblot, immunohistochemistry","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct protein identification by immunoblot and IHC with specific mAb, single lab but two orthogonal methods","pmids":["7757970"],"is_preprint":false},{"year":1996,"finding":"MAGE3 encodes an antigenic peptide (MEVDPIGHLY) presented by HLA-B44 molecules to CTL; CTL clones raised against this peptide recognized HLA-B44+ MAGE3-expressing tumor cell lines.","method":"HLA-B44 peptide binding assay, in vitro CTL induction, tumor cell lysis assay","journal":"Immunogenetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct peptide-MHC-CTL recognition assay with tumor cell killing, consistent with multiple prior epitope identification studies","pmids":["8606058"],"is_preprint":false},{"year":1996,"finding":"A second HLA-B44-restricted MAGE-3 epitope (M3-167, an 11-mer) was characterized; TAP binding studies showed M3-167 has ~9-fold higher TAP affinity than the 9-mer M3-168, and M3-167 (or a longer precursor) is proposed to be transported into the ER and trimmed for presentation by either HLA-A1 or HLA-B44.","method":"HLA-B44 alpha-chain refolding assay, in vitro CTL induction, TAP binding assay","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical TAP binding and MHC refolding assays, single lab","pmids":["8938145"],"is_preprint":false},{"year":1997,"finding":"IFN-γ gene transfer into HLA class I-deficient small cell lung cancer cells restored HLA class I and TAP-1/TAP-2 expression and enabled recognition by MAGE-3-specific HLA-A2-restricted CTL, establishing that HLA class I deficiency is the mechanism preventing CTL recognition of MAGE-3 in SCLC.","method":"Stable IFN-γ gene transfection, RT-PCR for TAP-1/TAP-2, CTL cytotoxicity assay","journal":"Gene therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function (HLA-deficient) rescued by gain-of-function (IFN-γ transfection), functional CTL readout, single lab","pmids":["9415308"],"is_preprint":false},{"year":1999,"finding":"The HLA-A*0201-restricted MAGE-3271-279 peptide is not efficiently generated from full-length MAGE-3 protein by the proteasome under normal conditions; inhibition of specific proteasome activities by lactacystin rescued generation of the COOH terminus of the antigenic peptide and enabled CTL recognition of MAGE-3-expressing melanoma cells, demonstrating that proteasomal activity modulates presentation of this epitope.","method":"Minigene CTL assay, in vitro proteasome digestion of synthetic peptides, lactacystin inhibition of proteasome, CTL lysis assay of lactacystin-treated tumor cells","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with purified proteasome, pharmacological inhibition in vitro and in cellulo with functional CTL readout, multiple orthogonal methods","pmids":["10075973"],"is_preprint":false},{"year":1999,"finding":"MAGE-3 protein is processed and two HLA class II epitopes (MAGE-3114-127 and MAGE-3121-134) presented by HLA-DR13 to CD4+ T lymphocytes were identified by loading monocyte-derived dendritic cells with recombinant MAGE-3 protein.","method":"Dendritic cell loading with recombinant MAGE-3 protein, CD4+ T cell clone isolation, HLA-DR13 restriction confirmed by antibody blocking","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution of antigen processing/presentation with recombinant protein in human DCs, epitope mapping confirmed by T cell clones, replicated in same issue by independent lab","pmids":["10049940"],"is_preprint":false},{"year":1999,"finding":"A MAGE-3 epitope (MAGE-3281-295) is presented by HLA-DR11 to CD4+ T cells; cold target inhibition confirmed recognition of this epitope on the surface of HLA-DR11/MAGE-3-positive melanoma cells by cytolytic CD4+ T cells of the Th1 type.","method":"TEPITOPE prediction, synthetic peptide stimulation of CD4+ T cells, cold target inhibition assay, cytotoxicity assay against melanoma cells","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — functional CD4+ T cell cytotoxicity against tumor cells confirmed by cold target competition, two independent labs published simultaneously","pmids":["10049951"],"is_preprint":false},{"year":2000,"finding":"Dendritic cells acquire MAGE-3 antigen from apoptotic bodies of irradiated MAGE-3-expressing cells via phagocytosis and present MAGE-3-derived epitopes via HLA-A*B5201 to induce MAGE-3-specific CTL, demonstrating cross-presentation of this intracytoplasmic tumor antigen.","method":"Apoptosis monitoring (annexin V/propidium iodide), DC phagocytosis assay, in vitro CTL induction from melanoma patient lymphocytes, tumor cell lysis assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional demonstration of cross-presentation mechanism, single lab, two orthogonal approaches (apoptosis + CTL induction)","pmids":["10681453"],"is_preprint":false},{"year":2000,"finding":"A MAGE-A3 epitope (TQHFVQENYLEY) presented by HLA-DP4 to CD4+ T cells was identified; CD4+ T cells recognizing this epitope lysed HLA-DP4+ MAGE-A3-expressing tumor cells, indicating endogenous class II presentation on tumor cell surface.","method":"CD4+ T cell clone isolation, HLA-DP4 restriction confirmation, tumor cell cytotoxicity assay","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 / Strong — epitope presented on tumor cell surface confirmed by cytotoxicity assay, HLA restriction confirmed, landmark finding replicated extensively in subsequent vaccine trials","pmids":["11103782"],"is_preprint":false},{"year":2001,"finding":"A MAGE-A3 T helper epitope (MAGE-A3146-160) is recognized in the context of HLA-DR4 and HLA-DR7 and is naturally processed from tumor cell lysates, dead/apoptotic tumor cells, and recombinant MAGE-A3 protein by antigen-presenting cells, enabling CD4+ Th responses.","method":"In vitro T helper cell induction with peptide, tumor cell lysates, apoptotic cells, and recombinant protein; HLA restriction by antibody blocking","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — natural processing confirmed with multiple antigen forms and two HLA alleles, single lab","pmids":["11406551"],"is_preprint":false},{"year":2002,"finding":"Four immunodominant regions (residues 111-125, 146-160, 191-205, and 281-295) of MAGE-3 were identified as naturally processed, promiscuous HLA-DR-restricted CD4+ T cell epitopes recognized in association with 3-4 different HLA-DR alleles; regions 161-175 and 171-185 were not naturally processed in vitro.","method":"TEPITOPE prediction, HLA-DR binding assay, CD4+ T cell proliferation assay, natural processing confirmed by T cell recognition of protein-loaded APCs vs. synthetic peptides","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic epitope mapping with natural processing confirmation, single lab, multiple alleles tested","pmids":["12393675"],"is_preprint":false},{"year":2003,"finding":"A MAGE-3 epitope (ACYEFLWGPRALVETS, MAGE-3267-282) restricted by HLA-DR1 was identified; CD4+ T cell clones with this specificity were isolated from a vaccinated melanoma patient, and one clone with high LFA-1 expression lysed DR1+/MAGE-3+ tumor cells; a second clone showed cross-reactivity with homologous peptides from MAGE-1, -2, -4, -6, -10, and -11.","method":"CD4+ T cell clone isolation from vaccinated patient, TCR sequencing, tumor cell cytotoxicity assay, cross-reactivity panel","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct tumor cell killing by patient-derived CD4+ T cells, cross-reactivity established experimentally, single lab","pmids":["12817001"],"is_preprint":false},{"year":2007,"finding":"MAGE-A3 expression is regulated by the balance between histone H3 acetylation and methylation at the MAGE-A3 promoter; FGF7/FGFR2-IIIb signaling suppresses MAGE-A3 expression by promoting histone H3 methylation, while estradiol induces expression via enhanced H3 acetylation; downregulation of MAGE-A3 induces p53 transcription via reciprocal histone modifications.","method":"Chromatin immunoprecipitation (ChIP) for histone marks, methylation-specific PCR, combined bisulfite restriction analysis, reverse transcription-PCR, estradiol and FGF7 treatment of pituitary cell lines","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP with multiple histone marks, pharmacological modulation, single lab with multiple orthogonal methods","pmids":["18381936"],"is_preprint":false},{"year":2007,"finding":"Methyl-CpG binding proteins MBD1 and MeCP2 bind in vivo to the methylated MAGE-A3 promoter and repress its transcriptional activity; MBD1 splice variants (1v1 and 1v3) also repress unmethylated MAGE-A3 promoter activity; MBD2a had no inhibitory effect on MAGE-A3 promoters but up-regulated basal promoter activity.","method":"Electrophoretic mobility shift assay (EMSA), chromatin immunoprecipitation (ChIP), transient transfection/luciferase reporter assay in MCF-7 and Mbd1-deficient fibroblasts, co-transfection experiments","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA, ChIP, and functional reporter assays combined, single lab, multiple MBD proteins compared","pmids":["17634428"],"is_preprint":false},{"year":2009,"finding":"RNA interference-mediated knockdown of MAGE-A3 in multiple myeloma cell lines induced apoptosis, reduced survival of clonogenic myeloma precursors, and enhanced sensitivity to conventional chemotherapy, establishing a pro-survival function for MAGE-A3 in myeloma cells that is independent of cell proliferation or adhesion.","method":"siRNA knockdown of MAGE-A3 in myeloma cell lines, functional assays for proliferation, adhesion, apoptosis, colony formation, chemosensitivity","journal":"Haematologica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi loss-of-function with multiple functional readouts, single lab","pmids":["20015885"],"is_preprint":false},{"year":2011,"finding":"BORIS binds to the MAGEA3 promoter in lung cancer cells and induces MAGEA3 transcription by promoting activating histone modifications (H3 acetylation/permissive marks) and, for MAGEA3 specifically, by causing promoter demethylation; BORIS knockdown reduced MAGEA3 expression, while BORIS induction increased it.","method":"ChIP for BORIS and histone marks, luciferase reporter assay, BORIS induction and knockdown, methylation analysis, RT-PCR for MAGE-A3 expression","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, promoter reporter, and expression correlation with BORIS gain/loss-of-function, single lab with multiple methods","pmids":["21558405"],"is_preprint":false},{"year":2016,"finding":"MAGE-A3 knockdown in MKN1 gastric cancer cells reduced proliferation and colony formation, regulated Bax and p21 expression under stress conditions, and increased Puma and Noxa expression, enhancing docetaxel sensitivity; these effects were associated with epigenetic regulation of MAGE-A3 by promoter methylation.","method":"miRNA-mediated MAGE-A3 knockdown, cell proliferation assay, colony formation assay, apoptosis assay, cell cycle analysis, Western blot for Bax, p21, Puma, Noxa, drug sensitivity assay","journal":"Cellular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with multiple cellular and molecular readouts, single lab","pmids":["26868260"],"is_preprint":false},{"year":2018,"finding":"miR-1273g-3p targets the 3'UTR of MAGEA3/6 to suppress their expression; MAGEA3/6 silencing via shRNA or miR-1273g-3p leads to AMPKα1 upregulation, inhibition of colorectal cancer cell proliferation, and apoptosis; the anti-cancer activity was blocked by AMPKα1 knockout, establishing that MAGEA3/6 promote cancer cell growth by suppressing AMPKα1.","method":"Bioinformatic target prediction, RNA pull-down and RIP assay to confirm miR-31-5p binding, shRNA knockdown, miRNA overexpression, AMPKα1 knockout, in vitro proliferation/apoptosis assays, in vivo xenograft tumor growth assay","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA pull-down confirms binding, loss-of-function with genetic rescue (AMPKα1 KO blocks effects), in vivo validation, single lab","pmids":["30056111"],"is_preprint":false},{"year":2019,"finding":"MAGE-A3 overexpression facilitates cervical cancer cell proliferation, migration, and invasion by activating EMT markers and the Wnt signaling pathway; MAGE-A3 knockdown suppressed EMT and Wnt signaling and reduced in vivo tumor growth.","method":"qRT-PCR, loss-of-function (siRNA knockdown) and gain-of-function (overexpression) in HeLa and SiHa cells, Western blot for EMT and Wnt pathway proteins, in vivo tumorigenesis assay","journal":"Biomedicine & pharmacotherapy","confidence":"Low","confidence_rationale":"Tier 3 / Weak — Western blot for pathway markers is indirect; Wnt pathway activation not confirmed by direct Wnt reporter or target gene rescue; single lab, no rescue experiment","pmids":["31918280"],"is_preprint":false},{"year":2019,"finding":"MAGE-A3 expression in hepatocellular carcinoma is regulated by miR-31-5p; MAGEA3 depletion inhibited proliferation, invasion, and cisplatin resistance of HCC cells and reduced expression of drug resistance proteins MRP2, MRP3, and MDR-1; LINC01234 acts as a competing endogenous RNA to sponge miR-31-5p and thereby restore MAGEA3 expression.","method":"siRNA knockdown of MAGEA3, RNA pull-down and RIP assay for LINC01234/miR-31-5p/MAGEA3 binding, in vitro proliferation, invasion, and apoptosis assays, Western blot for MRP2, MRP3, MDR-1, ALB","journal":"Molecular therapy. Nucleic acids","confidence":"Low","confidence_rationale":"Tier 3 / Weak — mechanistic axis demonstrated by RIP/pull-down but rescue experiments use expression constructs without rigorous controls; single lab","pmids":["31838274"],"is_preprint":false},{"year":2012,"finding":"Receptor-mediated uptake of MAGE-A3 antigen by dendritic cells (via Fcγ receptor using antibody-opsonized protein, or via phagocytosis of bortezomib-treated apoptotic myeloma cells) favors cross-presentation and induction of CD8+ T cells, whereas macropinocytosis of uncoated protein preferentially induces CD4+ T cell priming.","method":"MAGE-A3 protein uptake assay with antibody opsonization, Fcγ receptor blocking, bortezomib-induced immunogenic apoptosis assay with hsp90 surface staining, phagocytosis assay, CD4+ and CD8+ T cell priming assays","journal":"Cancer immunology, immunotherapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor-specific uptake confirmed by blocking, functional T cell differentiation outcomes measured, single lab with orthogonal antigen delivery methods","pmids":["22562379"],"is_preprint":false}],"current_model":"MAGEA3 encodes a ~48 kDa cytoplasmic cancer-germline protein that functions as a pro-survival factor in tumor cells (suppressing apoptosis at least partly by inhibiting AMPKα1 degradation and regulating Bax/p21/Puma/Noxa), whose promoter is epigenetically silenced in normal somatic tissues by DNA methylation and MBD1/MeCP2-mediated histone modifications but de-repressed in cancer through promoter demethylation and BORIS-driven chromatin remodeling; it presents multiple antigenic peptides via HLA class I (A1, A2, B44) and class II (DR1, DR11, DR13, DP4) molecules to cytolytic CD8+ and CD4+ T cells, with proteasomal processing of certain epitopes (e.g., MAGE-3271-279) being regulated by selective inhibition of specific proteasome activities."},"narrative":{"mechanistic_narrative":"MAGEA3 is a cancer-germline gene whose product is a ~48 kDa cytoplasmic protein that acts as a pro-survival factor in tumor cells while serving as a tumor-rejection antigen [PMID:7757970, PMID:20015885]. As an antigen, full-length MAGE-A3 protein is processed into multiple epitopes presented on HLA class I molecules — including HLA-A1, HLA-A2, and HLA-B44 — to cytolytic CD8+ T cells [PMID:8113684, PMID:7805731, PMID:8606058], and into numerous promiscuous HLA class II epitopes (DR1, DR4/DR7, DR11, DR13, DP4) recognized by CD4+ T cells, several of which directly lyse antigen-positive tumor cells [PMID:10049940, PMID:10049951, PMID:11103782, PMID:12817001]. Presentation of certain class I epitopes is tuned at the proteasomal level: the HLA-A*0201-restricted MAGE-3271-279 peptide is poorly generated under normal conditions and its production is rescued by selective proteasome inhibition [PMID:10075973], and class I deficiency in lung cancer cells abrogates CTL recognition until IFN-γ restores HLA and TAP expression [PMID:9415308]. Because the protein is intracytoplasmic, dendritic cells acquire it by cross-presentation from apoptotic tumor bodies, with the uptake route (Fcγ-receptor versus macropinocytosis) biasing whether CD8+ or CD4+ responses are primed [PMID:10681453, PMID:22562379]. Functionally, MAGE-A3 supports tumor cell survival and chemoresistance: its knockdown induces apoptosis, modulates Bax/p21/Puma/Noxa, and sensitizes cells to chemotherapy [PMID:20015885, PMID:26868260], and it promotes proliferation in part by suppressing AMPKα1, since AMPKα1 knockout abolishes the anti-tumor effect of MAGE-A3 silencing [PMID:30056111]. Expression is governed epigenetically — silenced in normal tissue by promoter methylation and methyl-CpG-binding proteins MBD1 and MeCP2, and by histone H3 methylation/acetylation balance — and de-repressed in cancer through BORIS-driven activating chromatin modifications and promoter demethylation [PMID:18381936, PMID:17634428, PMID:21558405].","teleology":[{"year":1994,"claim":"Established MAGE-A3 as a bona fide tumor antigen by showing its product is recognized by autologous CTL, defining the first HLA-A1-restricted epitope and its binding anchor residues.","evidence":"Autologous CTL recognition and alanine-scanning peptide competition on melanoma cells","pmids":["8113684","7805731"],"confidence":"High","gaps":["Did not address how the epitope is generated intracellularly","Restricted to HLA-A1 and HLA-A2 contexts initially"]},{"year":1995,"claim":"Defined the physical product of the gene, showing MAGE-A3 is a ~48 kDa cytoplasmic protein.","evidence":"Monoclonal antibody immunoblot and immunohistochemistry on expressing cell lines","pmids":["7757970"],"confidence":"Medium","gaps":["No domain or biochemical activity assigned","Single-lab antibody characterization"]},{"year":1996,"claim":"Extended the antigenic repertoire to HLA-B44 and probed the antigen-processing pathway, linking TAP affinity to epitope availability.","evidence":"HLA-B44 refolding, CTL induction, and TAP binding assays","pmids":["8606058","8938145"],"confidence":"High","gaps":["Precise trimming steps in the ER not defined","TAP-binding model for the 11-mer remains a proposed mechanism"]},{"year":1999,"claim":"Resolved why some epitopes escape recognition by showing proteasome activity gates generation of MAGE-3271-279, and broadened the picture to CD4+ T-cell recognition via multiple class II alleles.","evidence":"In vitro proteasome digestion with lactacystin and CTL assays; DC loading with recombinant protein and CD4+ T-cell clones (HLA-DR13, DR11)","pmids":["10075973","10049940","10049951"],"confidence":"High","gaps":["Which specific proteasome subunit activities cleave the epitope not fully resolved","Class II processing compartment not mapped"]},{"year":2000,"claim":"Demonstrated how an intracytoplasmic antigen reaches T cells, establishing cross-presentation of MAGE-A3 from apoptotic tumor cells and adding HLA-DP4 class II presentation on tumor surfaces.","evidence":"DC phagocytosis of apoptotic bodies with CTL induction; CD4+ T-cell lysis of HLA-DP4+ tumor cells","pmids":["10681453","11103782"],"confidence":"Medium","gaps":["Receptor mediating apoptotic body uptake not yet identified","Efficiency of cross-presentation in vivo unknown"]},{"year":2002,"claim":"Systematically mapped naturally processed, promiscuous HLA-DR CD4+ epitopes, distinguishing processed from non-processed regions.","evidence":"TEPITOPE prediction, HLA-DR binding, and natural-processing confirmation with protein-loaded APCs","pmids":["12393675","11406551","12817001"],"confidence":"Medium","gaps":["Single-lab epitope mapping","Cross-reactivity with other MAGE family members not exhaustively characterized"]},{"year":2009,"claim":"Shifted the picture from antigen to functional driver by showing MAGE-A3 is required for tumor cell survival independent of proliferation or adhesion.","evidence":"siRNA knockdown in multiple myeloma lines with apoptosis, clonogenic, and chemosensitivity readouts","pmids":["20015885"],"confidence":"Medium","gaps":["Molecular partners mediating survival not identified here","Single tumor type"]},{"year":2007,"claim":"Defined the epigenetic logic of MAGE-A3 silencing and de-repression, implicating promoter methylation, methyl-CpG-binding proteins, and histone-mark balance.","evidence":"ChIP, EMSA, methylation analysis, and luciferase reporters with MBD1/MeCP2 and FGF7/estradiol modulation","pmids":["18381936","17634428"],"confidence":"Medium","gaps":["Direct demethylase machinery not identified","In vivo relevance to tumor expression incompletely established"]},{"year":2011,"claim":"Identified BORIS as a transcriptional activator that de-represses MAGEA3 in cancer via activating histone marks and promoter demethylation.","evidence":"ChIP, reporter assays, and BORIS gain/loss-of-function with methylation analysis in lung cancer cells","pmids":["21558405"],"confidence":"Medium","gaps":["Mechanism of BORIS-induced demethylation unresolved","Single lab"]},{"year":2018,"claim":"Provided a molecular pro-survival mechanism, showing MAGE-A3/6 promote tumor growth by suppressing AMPKα1, with genetic rescue confirming the axis.","evidence":"shRNA/miR-1273g-3p silencing, AMPKα1 knockout rescue, and xenograft growth assays","pmids":["30056111","26868260"],"confidence":"Medium","gaps":["Direct biochemical link between MAGE-A3 and AMPKα1 degradation not reconstituted in these data","Bax/p21/Puma/Noxa regulation correlative"]},{"year":2019,"claim":"Connected MAGE-A3 to additional oncogenic pathways and non-coding RNA regulation in cervical and hepatocellular carcinoma.","evidence":"Gain/loss-of-function with EMT/Wnt marker blots; miR-31-5p/LINC01234 ceRNA axis with RIP and drug-resistance protein analysis","pmids":["31918280","31838274"],"confidence":"Low","gaps":["Wnt activation shown only by marker blots without reporter or rescue","ceRNA rescue lacks rigorous controls; single lab"]},{"year":null,"claim":"How the cytoplasmic MAGE-A3 protein biochemically engages AMPKα1, the apoptotic machinery, and its degradation pathway to mediate tumor cell survival remains undefined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No direct binding partner or structural model for the survival function","Mechanism linking antigen-processing biology to oncogenic function unexplored"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[19,16]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,3,7,8,10]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[16,18,19]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[14,15,17]}],"complexes":[],"partners":["AMPKΑ1","MBD1","MECP2","BORIS"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P43357","full_name":"Melanoma-associated antigen 3","aliases":["Antigen MZ2-D","Cancer/testis antigen 1.3","CT1.3","MAGE-3 antigen"],"length_aa":314,"mass_kda":34.7,"function":"Activator of ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases that acts as a repressor of autophagy (PubMed:20864041, PubMed:31267705). May enhance ubiquitin ligase activity of TRIM28 and stimulate p53/TP53 ubiquitination by TRIM28. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex (PubMed:17942928, PubMed:20864041). May play a role in embryonal development and tumor transformation or aspects of tumor progression (PubMed:17942928, PubMed:20864041). In vitro promotes cell viability in melanoma cell lines (PubMed:17942928). Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes (PubMed:8113684)","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/P43357/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MAGEA3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":5,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MAGEA3","total_profiled":1310},"omim":[{"mim_id":"620087","title":"DDB1- AND CUL4-ASSOCIATED FACTOR 12; DCAF12","url":"https://www.omim.org/entry/620087"},{"mim_id":"300599","title":"G ANTIGEN 6; GAGE6","url":"https://www.omim.org/entry/300599"},{"mim_id":"300598","title":"G ANTIGEN 5; GAGE5","url":"https://www.omim.org/entry/300598"},{"mim_id":"300597","title":"G ANTIGEN 4; GAGE4","url":"https://www.omim.org/entry/300597"},{"mim_id":"300596","title":"G ANTIGEN 3; GAGE3","url":"https://www.omim.org/entry/300596"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in single","driving_tissues":[{"tissue":"testis","ntpm":7.6}],"url":"https://www.proteinatlas.org/search/MAGEA3"},"hgnc":{"alias_symbol":["HYPD","HIP8","MGC14613","CT1.3"],"prev_symbol":["MAGE3"]},"alphafold":{"accession":"P43357","domains":[{"cath_id":"1.10.10.1200","chopping":"104-184","consensus_level":"high","plddt":92.6422,"start":104,"end":184},{"cath_id":"1.10.10.1210","chopping":"199-295","consensus_level":"high","plddt":88.1838,"start":199,"end":295}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P43357","model_url":"https://alphafold.ebi.ac.uk/files/AF-P43357-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P43357-F1-predicted_aligned_error_v6.png","plddt_mean":71.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MAGEA3","jax_strain_url":"https://www.jax.org/strain/search?query=MAGEA3"},"sequence":{"accession":"P43357","fasta_url":"https://rest.uniprot.org/uniprotkb/P43357.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P43357/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P43357"}},"corpus_meta":[{"pmid":"8113684","id":"PMC_8113684","title":"Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes.","date":"1994","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8113684","citation_count":713,"is_preprint":false},{"pmid":"9935203","id":"PMC_9935203","title":"Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.","date":"1999","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9935203","citation_count":673,"is_preprint":false},{"pmid":"27132212","id":"PMC_27132212","title":"Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.","date":"2016","source":"The Lancet. Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27132212","citation_count":410,"is_preprint":false},{"pmid":"7805731","id":"PMC_7805731","title":"A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.","date":"1994","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7805731","citation_count":360,"is_preprint":false},{"pmid":"23715562","id":"PMC_23715562","title":"Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.","date":"2013","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23715562","citation_count":319,"is_preprint":false},{"pmid":"23715567","id":"PMC_23715567","title":"Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.","date":"2013","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23715567","citation_count":251,"is_preprint":false},{"pmid":"28809608","id":"PMC_28809608","title":"Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.","date":"2017","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28809608","citation_count":232,"is_preprint":false},{"pmid":"23715572","id":"PMC_23715572","title":"Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.","date":"2013","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23715572","citation_count":180,"is_preprint":false},{"pmid":"10049951","id":"PMC_10049951","title":"Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.","date":"1999","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10049951","citation_count":177,"is_preprint":false},{"pmid":"10049940","id":"PMC_10049940","title":"Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes.","date":"1999","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10049940","citation_count":176,"is_preprint":false},{"pmid":"11517302","id":"PMC_11517302","title":"A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11517302","citation_count":175,"is_preprint":false},{"pmid":"10975870","id":"PMC_10975870","title":"Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10975870","citation_count":170,"is_preprint":false},{"pmid":"15153480","id":"PMC_15153480","title":"Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15153480","citation_count":169,"is_preprint":false},{"pmid":"29908991","id":"PMC_29908991","title":"MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.","date":"2018","source":"The Lancet. Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29908991","citation_count":153,"is_preprint":false},{"pmid":"14978137","id":"PMC_14978137","title":"Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/14978137","citation_count":148,"is_preprint":false},{"pmid":"21149604","id":"PMC_21149604","title":"A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21149604","citation_count":144,"is_preprint":false},{"pmid":"26105625","id":"PMC_26105625","title":"A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma.","date":"2015","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/26105625","citation_count":140,"is_preprint":false},{"pmid":"12504661","id":"PMC_12504661","title":"Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report.","date":"2003","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/12504661","citation_count":134,"is_preprint":false},{"pmid":"15945101","id":"PMC_15945101","title":"Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.","date":"2005","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15945101","citation_count":128,"is_preprint":false},{"pmid":"18216244","id":"PMC_18216244","title":"Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18216244","citation_count":127,"is_preprint":false},{"pmid":"7757970","id":"PMC_7757970","title":"Identification and intracellular location of MAGE-3 gene product.","date":"1995","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7757970","citation_count":124,"is_preprint":false},{"pmid":"11103782","id":"PMC_11103782","title":"A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes.","date":"2000","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11103782","citation_count":117,"is_preprint":false},{"pmid":"14690745","id":"PMC_14690745","title":"Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study.","date":"2004","source":"European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/14690745","citation_count":116,"is_preprint":false},{"pmid":"10681453","id":"PMC_10681453","title":"Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10681453","citation_count":114,"is_preprint":false},{"pmid":"12875607","id":"PMC_12875607","title":"Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease.","date":"2003","source":"Cancer immunity","url":"https://pubmed.ncbi.nlm.nih.gov/12875607","citation_count":108,"is_preprint":false},{"pmid":"10546159","id":"PMC_10546159","title":"A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma.","date":"1999","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/10546159","citation_count":107,"is_preprint":false},{"pmid":"8606058","id":"PMC_8606058","title":"A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3.","date":"1996","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/8606058","citation_count":102,"is_preprint":false},{"pmid":"10741395","id":"PMC_10741395","title":"The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells.","date":"2000","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10741395","citation_count":102,"is_preprint":false},{"pmid":"11205913","id":"PMC_11205913","title":"Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide.","date":"2001","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/11205913","citation_count":94,"is_preprint":false},{"pmid":"11300489","id":"PMC_11300489","title":"Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12.","date":"2001","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/11300489","citation_count":91,"is_preprint":false},{"pmid":"10075973","id":"PMC_10075973","title":"Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3.","date":"1999","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10075973","citation_count":90,"is_preprint":false},{"pmid":"15504408","id":"PMC_15504408","title":"The complex between hydrogenase-maturation proteins HypC and HypD is an intermediate in the supply of cyanide to the active site iron of [NiFe]-hydrogenases.","date":"2004","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15504408","citation_count":88,"is_preprint":false},{"pmid":"20015885","id":"PMC_20015885","title":"Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells.","date":"2009","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/20015885","citation_count":79,"is_preprint":false},{"pmid":"9403705","id":"PMC_9403705","title":"MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.","date":"1997","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9403705","citation_count":78,"is_preprint":false},{"pmid":"21626030","id":"PMC_21626030","title":"MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.","date":"2011","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/21626030","citation_count":76,"is_preprint":false},{"pmid":"18292586","id":"PMC_18292586","title":"Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18292586","citation_count":76,"is_preprint":false},{"pmid":"19435913","id":"PMC_19435913","title":"The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19435913","citation_count":76,"is_preprint":false},{"pmid":"14770084","id":"PMC_14770084","title":"Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors.","date":"2004","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/14770084","citation_count":75,"is_preprint":false},{"pmid":"22596240","id":"PMC_22596240","title":"Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma.","date":"2012","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22596240","citation_count":71,"is_preprint":false},{"pmid":"11216765","id":"PMC_11216765","title":"Induction of MAGE-3 expression in lung and esophageal cancer cells.","date":"2001","source":"The Annals of thoracic surgery","url":"https://pubmed.ncbi.nlm.nih.gov/11216765","citation_count":70,"is_preprint":false},{"pmid":"12784237","id":"PMC_12784237","title":"Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma.","date":"2003","source":"Head & neck","url":"https://pubmed.ncbi.nlm.nih.gov/12784237","citation_count":70,"is_preprint":false},{"pmid":"30546947","id":"PMC_30546947","title":"Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials.","date":"2018","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/30546947","citation_count":70,"is_preprint":false},{"pmid":"9862732","id":"PMC_9862732","title":"HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9862732","citation_count":69,"is_preprint":false},{"pmid":"11406551","id":"PMC_11406551","title":"Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11406551","citation_count":68,"is_preprint":false},{"pmid":"12393675","id":"PMC_12393675","title":"Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12393675","citation_count":66,"is_preprint":false},{"pmid":"26100270","id":"PMC_26100270","title":"MAGE-A3: an immunogenic target used in clinical practice.","date":"2015","source":"Immunotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/26100270","citation_count":64,"is_preprint":false},{"pmid":"23728352","id":"PMC_23728352","title":"Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients.","date":"2013","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/23728352","citation_count":63,"is_preprint":false},{"pmid":"25537079","id":"PMC_25537079","title":"A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).","date":"2014","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/25537079","citation_count":63,"is_preprint":false},{"pmid":"24457462","id":"PMC_24457462","title":"Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma.","date":"2014","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/24457462","citation_count":60,"is_preprint":false},{"pmid":"9378560","id":"PMC_9378560","title":"Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine.","date":"1997","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9378560","citation_count":59,"is_preprint":false},{"pmid":"18381936","id":"PMC_18381936","title":"Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia.","date":"2008","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/18381936","citation_count":59,"is_preprint":false},{"pmid":"31838274","id":"PMC_31838274","title":"LINC01234/MicroRNA-31-5p/MAGEA3 Axis Mediates the Proliferation and Chemoresistance of Hepatocellular Carcinoma Cells.","date":"2019","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/31838274","citation_count":58,"is_preprint":false},{"pmid":"16331618","id":"PMC_16331618","title":"The clinical significance of MAGEA3 expression in pancreatic cancer.","date":"2006","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16331618","citation_count":57,"is_preprint":false},{"pmid":"11857021","id":"PMC_11857021","title":"Evaluation of MAGE-1 and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma cells.","date":"2002","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11857021","citation_count":54,"is_preprint":false},{"pmid":"22287423","id":"PMC_22287423","title":"Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma.","date":"2012","source":"Head & neck","url":"https://pubmed.ncbi.nlm.nih.gov/22287423","citation_count":54,"is_preprint":false},{"pmid":"26309191","id":"PMC_26309191","title":"Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer.","date":"2015","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26309191","citation_count":51,"is_preprint":false},{"pmid":"8900375","id":"PMC_8900375","title":"Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma.","date":"1996","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8900375","citation_count":48,"is_preprint":false},{"pmid":"30056111","id":"PMC_30056111","title":"miR-1273g silences MAGEA3/6 to inhibit human colorectal cancer cell growth via activation of AMPK signaling.","date":"2018","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/30056111","citation_count":47,"is_preprint":false},{"pmid":"21558405","id":"PMC_21558405","title":"BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3, and MAGEA4, is associated with their transcriptional activation in lung cancer.","date":"2011","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/21558405","citation_count":47,"is_preprint":false},{"pmid":"14500399","id":"PMC_14500399","title":"Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/14500399","citation_count":47,"is_preprint":false},{"pmid":"9415308","id":"PMC_9415308","title":"IFN-gamma gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer.","date":"1997","source":"Gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/9415308","citation_count":46,"is_preprint":false},{"pmid":"16814778","id":"PMC_16814778","title":"Properties of the [NiFe]-hydrogenase maturation protein HypD.","date":"2006","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/16814778","citation_count":44,"is_preprint":false},{"pmid":"15570431","id":"PMC_15570431","title":"MAGE-A3 is a frequent tumor antigen of metastasized melanoma.","date":"2004","source":"Archives of dermatological research","url":"https://pubmed.ncbi.nlm.nih.gov/15570431","citation_count":44,"is_preprint":false},{"pmid":"19074732","id":"PMC_19074732","title":"Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19074732","citation_count":43,"is_preprint":false},{"pmid":"23390371","id":"PMC_23390371","title":"MAGE-A3 is highly expressed in a subset of colorectal cancer patients.","date":"2012","source":"Cancer immunity","url":"https://pubmed.ncbi.nlm.nih.gov/23390371","citation_count":42,"is_preprint":false},{"pmid":"23597401","id":"PMC_23597401","title":"HypD is the scaffold protein for Fe-(CN)2CO cofactor assembly in [NiFe]-hydrogenase maturation.","date":"2013","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23597401","citation_count":41,"is_preprint":false},{"pmid":"17634428","id":"PMC_17634428","title":"Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters.","date":"2007","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/17634428","citation_count":40,"is_preprint":false},{"pmid":"25031712","id":"PMC_25031712","title":"MAGE-A3 is highly expressed in a cancer stem cell-like side population of bladder cancer cells.","date":"2014","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25031712","citation_count":40,"is_preprint":false},{"pmid":"10472332","id":"PMC_10472332","title":"Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma.","date":"1999","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10472332","citation_count":36,"is_preprint":false},{"pmid":"12576432","id":"PMC_12576432","title":"Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma.","date":"2003","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/12576432","citation_count":36,"is_preprint":false},{"pmid":"17007017","id":"PMC_17007017","title":"Promoter hypomethylation and reactivation of MAGE-A1 and MAGE-A3 genes in colorectal cancer cell lines and cancer tissues.","date":"2006","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/17007017","citation_count":35,"is_preprint":false},{"pmid":"12817001","id":"PMC_12817001","title":"A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12817001","citation_count":33,"is_preprint":false},{"pmid":"11720472","id":"PMC_11720472","title":"Detection of MAGE-A3 in breast cancer patients' sentinel lymph nodes.","date":"2001","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11720472","citation_count":33,"is_preprint":false},{"pmid":"18049337","id":"PMC_18049337","title":"Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma.","date":"2007","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/18049337","citation_count":33,"is_preprint":false},{"pmid":"8900370","id":"PMC_8900370","title":"MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumors.","date":"1996","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8900370","citation_count":32,"is_preprint":false},{"pmid":"30189381","id":"PMC_30189381","title":"Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?","date":"2018","source":"Breast (Edinburgh, Scotland)","url":"https://pubmed.ncbi.nlm.nih.gov/30189381","citation_count":32,"is_preprint":false},{"pmid":"26581199","id":"PMC_26581199","title":"A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.","date":"2015","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/26581199","citation_count":32,"is_preprint":false},{"pmid":"15756604","id":"PMC_15756604","title":"Heat shock protein 70/MAGE-3 fusion protein vaccine can enhance cellular and humoral immune responses to MAGE-3 in vivo.","date":"2005","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/15756604","citation_count":32,"is_preprint":false},{"pmid":"30567529","id":"PMC_30567529","title":"A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma.","date":"2018","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30567529","citation_count":32,"is_preprint":false},{"pmid":"25564441","id":"PMC_25564441","title":"A Comprehensive Expression Analysis of Cancer Testis Antigens in Head and Neck Squamous Cell Carcinoma Revels MAGEA3/6 as a Marker for Recurrence.","date":"2015","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/25564441","citation_count":31,"is_preprint":false},{"pmid":"26868260","id":"PMC_26868260","title":"Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer.","date":"2016","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/26868260","citation_count":31,"is_preprint":false},{"pmid":"32382487","id":"PMC_32382487","title":"Next-Generation Cancer-Specific Hybrid Theranostic Nanomaterials: MAGE-A3 NIR Persistent Luminescence Nanoparticles Conjugated to Afatinib for In Situ Suppression of Lung Adenocarcinoma Growth and Metastasis.","date":"2020","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/32382487","citation_count":31,"is_preprint":false},{"pmid":"31096717","id":"PMC_31096717","title":"MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31096717","citation_count":29,"is_preprint":false},{"pmid":"27163739","id":"PMC_27163739","title":"Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy.","date":"2016","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/27163739","citation_count":29,"is_preprint":false},{"pmid":"11084678","id":"PMC_11084678","title":"Efficient expression of the tumor-associated antigen MAGE-3 in human dendritic cells, using an avian influenza virus vector.","date":"2000","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/11084678","citation_count":29,"is_preprint":false},{"pmid":"15756643","id":"PMC_15756643","title":"A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.","date":"2005","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15756643","citation_count":29,"is_preprint":false},{"pmid":"19610063","id":"PMC_19610063","title":"Quantitative expression and immunogenicity of MAGE-3 and -6 in upper aerodigestive tract cancer.","date":"2009","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19610063","citation_count":28,"is_preprint":false},{"pmid":"10530563","id":"PMC_10530563","title":"MAGE-1 and MAGE-3 tumor rejection antigens in human germ cell tumors.","date":"1999","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/10530563","citation_count":27,"is_preprint":false},{"pmid":"30797153","id":"PMC_30797153","title":"Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.","date":"2019","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/30797153","citation_count":27,"is_preprint":false},{"pmid":"15699177","id":"PMC_15699177","title":"Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15699177","citation_count":27,"is_preprint":false},{"pmid":"21171821","id":"PMC_21171821","title":"Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.","date":"2010","source":"Cytotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/21171821","citation_count":27,"is_preprint":false},{"pmid":"19835823","id":"PMC_19835823","title":"A Mage3/Heat Shock Protein70 DNA vaccine induces both innate and adaptive immune responses for the antitumor activity.","date":"2009","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/19835823","citation_count":26,"is_preprint":false},{"pmid":"22562379","id":"PMC_22562379","title":"Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes.","date":"2012","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/22562379","citation_count":26,"is_preprint":false},{"pmid":"18956370","id":"PMC_18956370","title":"Melanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitope.","date":"2008","source":"Biotechnology journal","url":"https://pubmed.ncbi.nlm.nih.gov/18956370","citation_count":26,"is_preprint":false},{"pmid":"8938145","id":"PMC_8938145","title":"Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3.","date":"1996","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8938145","citation_count":26,"is_preprint":false},{"pmid":"35987136","id":"PMC_35987136","title":"Chemical complementarity between tumor resident, T-cell receptor CDR3s and MAGEA3/6 correlates with increased melanoma survival: Potential relevance to MAGE vaccine auto-reactivity.","date":"2022","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35987136","citation_count":25,"is_preprint":false},{"pmid":"24671426","id":"PMC_24671426","title":"MAGE-A3 with cell-penetrating domain as an efficient therapeutic cancer vaccine.","date":"2014","source":"JAMA surgery","url":"https://pubmed.ncbi.nlm.nih.gov/24671426","citation_count":25,"is_preprint":false},{"pmid":"31918280","id":"PMC_31918280","title":"Aberrantly enhanced melanoma-associated antigen (MAGE)-A3 expression facilitates cervical cancer cell proliferation and metastasis via actuating Wnt signaling pathway.","date":"2019","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/31918280","citation_count":24,"is_preprint":false},{"pmid":"27794402","id":"PMC_27794402","title":"The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients.","date":"2016","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/27794402","citation_count":24,"is_preprint":false},{"pmid":"20857101","id":"PMC_20857101","title":"MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes.","date":"2010","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/20857101","citation_count":24,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":56487,"output_tokens":5953,"usd":0.129378,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14689,"output_tokens":3586,"usd":0.081547,"stage2_stop_reason":"end_turn"},"total_usd":0.210925,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"MAGE-3 (MAGEA3) gene encodes a tumor antigen recognized by autologous cytolytic T lymphocytes (CTL) on melanoma cell line MZ2-MEL; the antigenic peptide MZ2-D is presented by HLA-A1, and competition experiments with Ala-substituted peptides established that Asp at position 3 and Tyr at position 9 are essential for HLA-A1 binding.\",\n      \"method\": \"Autologous CTL recognition assay, single alanine-substituted peptide competition experiments\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct peptide-CTL recognition assay with systematic mutagenesis (Ala scanning), foundational paper replicated extensively\",\n      \"pmids\": [\"8113684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"MAGE-3 encodes a second antigenic peptide (FLWGPRALV) presented by HLA-A2 molecules that is recognized by CTL and can be used to stimulate peptide-specific CTL clones that kill HLA-A2+ MAGE-3-expressing tumor cell lines.\",\n      \"method\": \"HLA-A2 peptide binding assay, in vitro CTL induction with peptide-pulsed lymphoblasts, tumor cell killing assay\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution of peptide-MHC-CTL axis with functional killing readout, replicated by multiple subsequent studies\",\n      \"pmids\": [\"7805731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The MAGE-3 gene product was identified as a ~48,000 Mr cytoplasmic protein by immunoblotting with a monoclonal antibody generated against recombinant His-tagged MAGE-3; immunohistochemistry confirmed cytoplasmic localization in MAGE-3-expressing cell lines.\",\n      \"method\": \"Recombinant protein expression, metal chelation purification, monoclonal antibody generation, immunoblot, immunohistochemistry\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct protein identification by immunoblot and IHC with specific mAb, single lab but two orthogonal methods\",\n      \"pmids\": [\"7757970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"MAGE3 encodes an antigenic peptide (MEVDPIGHLY) presented by HLA-B44 molecules to CTL; CTL clones raised against this peptide recognized HLA-B44+ MAGE3-expressing tumor cell lines.\",\n      \"method\": \"HLA-B44 peptide binding assay, in vitro CTL induction, tumor cell lysis assay\",\n      \"journal\": \"Immunogenetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct peptide-MHC-CTL recognition assay with tumor cell killing, consistent with multiple prior epitope identification studies\",\n      \"pmids\": [\"8606058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"A second HLA-B44-restricted MAGE-3 epitope (M3-167, an 11-mer) was characterized; TAP binding studies showed M3-167 has ~9-fold higher TAP affinity than the 9-mer M3-168, and M3-167 (or a longer precursor) is proposed to be transported into the ER and trimmed for presentation by either HLA-A1 or HLA-B44.\",\n      \"method\": \"HLA-B44 alpha-chain refolding assay, in vitro CTL induction, TAP binding assay\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical TAP binding and MHC refolding assays, single lab\",\n      \"pmids\": [\"8938145\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"IFN-γ gene transfer into HLA class I-deficient small cell lung cancer cells restored HLA class I and TAP-1/TAP-2 expression and enabled recognition by MAGE-3-specific HLA-A2-restricted CTL, establishing that HLA class I deficiency is the mechanism preventing CTL recognition of MAGE-3 in SCLC.\",\n      \"method\": \"Stable IFN-γ gene transfection, RT-PCR for TAP-1/TAP-2, CTL cytotoxicity assay\",\n      \"journal\": \"Gene therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function (HLA-deficient) rescued by gain-of-function (IFN-γ transfection), functional CTL readout, single lab\",\n      \"pmids\": [\"9415308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The HLA-A*0201-restricted MAGE-3271-279 peptide is not efficiently generated from full-length MAGE-3 protein by the proteasome under normal conditions; inhibition of specific proteasome activities by lactacystin rescued generation of the COOH terminus of the antigenic peptide and enabled CTL recognition of MAGE-3-expressing melanoma cells, demonstrating that proteasomal activity modulates presentation of this epitope.\",\n      \"method\": \"Minigene CTL assay, in vitro proteasome digestion of synthetic peptides, lactacystin inhibition of proteasome, CTL lysis assay of lactacystin-treated tumor cells\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with purified proteasome, pharmacological inhibition in vitro and in cellulo with functional CTL readout, multiple orthogonal methods\",\n      \"pmids\": [\"10075973\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"MAGE-3 protein is processed and two HLA class II epitopes (MAGE-3114-127 and MAGE-3121-134) presented by HLA-DR13 to CD4+ T lymphocytes were identified by loading monocyte-derived dendritic cells with recombinant MAGE-3 protein.\",\n      \"method\": \"Dendritic cell loading with recombinant MAGE-3 protein, CD4+ T cell clone isolation, HLA-DR13 restriction confirmed by antibody blocking\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution of antigen processing/presentation with recombinant protein in human DCs, epitope mapping confirmed by T cell clones, replicated in same issue by independent lab\",\n      \"pmids\": [\"10049940\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"A MAGE-3 epitope (MAGE-3281-295) is presented by HLA-DR11 to CD4+ T cells; cold target inhibition confirmed recognition of this epitope on the surface of HLA-DR11/MAGE-3-positive melanoma cells by cytolytic CD4+ T cells of the Th1 type.\",\n      \"method\": \"TEPITOPE prediction, synthetic peptide stimulation of CD4+ T cells, cold target inhibition assay, cytotoxicity assay against melanoma cells\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — functional CD4+ T cell cytotoxicity against tumor cells confirmed by cold target competition, two independent labs published simultaneously\",\n      \"pmids\": [\"10049951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Dendritic cells acquire MAGE-3 antigen from apoptotic bodies of irradiated MAGE-3-expressing cells via phagocytosis and present MAGE-3-derived epitopes via HLA-A*B5201 to induce MAGE-3-specific CTL, demonstrating cross-presentation of this intracytoplasmic tumor antigen.\",\n      \"method\": \"Apoptosis monitoring (annexin V/propidium iodide), DC phagocytosis assay, in vitro CTL induction from melanoma patient lymphocytes, tumor cell lysis assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional demonstration of cross-presentation mechanism, single lab, two orthogonal approaches (apoptosis + CTL induction)\",\n      \"pmids\": [\"10681453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"A MAGE-A3 epitope (TQHFVQENYLEY) presented by HLA-DP4 to CD4+ T cells was identified; CD4+ T cells recognizing this epitope lysed HLA-DP4+ MAGE-A3-expressing tumor cells, indicating endogenous class II presentation on tumor cell surface.\",\n      \"method\": \"CD4+ T cell clone isolation, HLA-DP4 restriction confirmation, tumor cell cytotoxicity assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — epitope presented on tumor cell surface confirmed by cytotoxicity assay, HLA restriction confirmed, landmark finding replicated extensively in subsequent vaccine trials\",\n      \"pmids\": [\"11103782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"A MAGE-A3 T helper epitope (MAGE-A3146-160) is recognized in the context of HLA-DR4 and HLA-DR7 and is naturally processed from tumor cell lysates, dead/apoptotic tumor cells, and recombinant MAGE-A3 protein by antigen-presenting cells, enabling CD4+ Th responses.\",\n      \"method\": \"In vitro T helper cell induction with peptide, tumor cell lysates, apoptotic cells, and recombinant protein; HLA restriction by antibody blocking\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — natural processing confirmed with multiple antigen forms and two HLA alleles, single lab\",\n      \"pmids\": [\"11406551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Four immunodominant regions (residues 111-125, 146-160, 191-205, and 281-295) of MAGE-3 were identified as naturally processed, promiscuous HLA-DR-restricted CD4+ T cell epitopes recognized in association with 3-4 different HLA-DR alleles; regions 161-175 and 171-185 were not naturally processed in vitro.\",\n      \"method\": \"TEPITOPE prediction, HLA-DR binding assay, CD4+ T cell proliferation assay, natural processing confirmed by T cell recognition of protein-loaded APCs vs. synthetic peptides\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic epitope mapping with natural processing confirmation, single lab, multiple alleles tested\",\n      \"pmids\": [\"12393675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"A MAGE-3 epitope (ACYEFLWGPRALVETS, MAGE-3267-282) restricted by HLA-DR1 was identified; CD4+ T cell clones with this specificity were isolated from a vaccinated melanoma patient, and one clone with high LFA-1 expression lysed DR1+/MAGE-3+ tumor cells; a second clone showed cross-reactivity with homologous peptides from MAGE-1, -2, -4, -6, -10, and -11.\",\n      \"method\": \"CD4+ T cell clone isolation from vaccinated patient, TCR sequencing, tumor cell cytotoxicity assay, cross-reactivity panel\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct tumor cell killing by patient-derived CD4+ T cells, cross-reactivity established experimentally, single lab\",\n      \"pmids\": [\"12817001\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MAGE-A3 expression is regulated by the balance between histone H3 acetylation and methylation at the MAGE-A3 promoter; FGF7/FGFR2-IIIb signaling suppresses MAGE-A3 expression by promoting histone H3 methylation, while estradiol induces expression via enhanced H3 acetylation; downregulation of MAGE-A3 induces p53 transcription via reciprocal histone modifications.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) for histone marks, methylation-specific PCR, combined bisulfite restriction analysis, reverse transcription-PCR, estradiol and FGF7 treatment of pituitary cell lines\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP with multiple histone marks, pharmacological modulation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"18381936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Methyl-CpG binding proteins MBD1 and MeCP2 bind in vivo to the methylated MAGE-A3 promoter and repress its transcriptional activity; MBD1 splice variants (1v1 and 1v3) also repress unmethylated MAGE-A3 promoter activity; MBD2a had no inhibitory effect on MAGE-A3 promoters but up-regulated basal promoter activity.\",\n      \"method\": \"Electrophoretic mobility shift assay (EMSA), chromatin immunoprecipitation (ChIP), transient transfection/luciferase reporter assay in MCF-7 and Mbd1-deficient fibroblasts, co-transfection experiments\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA, ChIP, and functional reporter assays combined, single lab, multiple MBD proteins compared\",\n      \"pmids\": [\"17634428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"RNA interference-mediated knockdown of MAGE-A3 in multiple myeloma cell lines induced apoptosis, reduced survival of clonogenic myeloma precursors, and enhanced sensitivity to conventional chemotherapy, establishing a pro-survival function for MAGE-A3 in myeloma cells that is independent of cell proliferation or adhesion.\",\n      \"method\": \"siRNA knockdown of MAGE-A3 in myeloma cell lines, functional assays for proliferation, adhesion, apoptosis, colony formation, chemosensitivity\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi loss-of-function with multiple functional readouts, single lab\",\n      \"pmids\": [\"20015885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"BORIS binds to the MAGEA3 promoter in lung cancer cells and induces MAGEA3 transcription by promoting activating histone modifications (H3 acetylation/permissive marks) and, for MAGEA3 specifically, by causing promoter demethylation; BORIS knockdown reduced MAGEA3 expression, while BORIS induction increased it.\",\n      \"method\": \"ChIP for BORIS and histone marks, luciferase reporter assay, BORIS induction and knockdown, methylation analysis, RT-PCR for MAGE-A3 expression\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, promoter reporter, and expression correlation with BORIS gain/loss-of-function, single lab with multiple methods\",\n      \"pmids\": [\"21558405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MAGE-A3 knockdown in MKN1 gastric cancer cells reduced proliferation and colony formation, regulated Bax and p21 expression under stress conditions, and increased Puma and Noxa expression, enhancing docetaxel sensitivity; these effects were associated with epigenetic regulation of MAGE-A3 by promoter methylation.\",\n      \"method\": \"miRNA-mediated MAGE-A3 knockdown, cell proliferation assay, colony formation assay, apoptosis assay, cell cycle analysis, Western blot for Bax, p21, Puma, Noxa, drug sensitivity assay\",\n      \"journal\": \"Cellular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with multiple cellular and molecular readouts, single lab\",\n      \"pmids\": [\"26868260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"miR-1273g-3p targets the 3'UTR of MAGEA3/6 to suppress their expression; MAGEA3/6 silencing via shRNA or miR-1273g-3p leads to AMPKα1 upregulation, inhibition of colorectal cancer cell proliferation, and apoptosis; the anti-cancer activity was blocked by AMPKα1 knockout, establishing that MAGEA3/6 promote cancer cell growth by suppressing AMPKα1.\",\n      \"method\": \"Bioinformatic target prediction, RNA pull-down and RIP assay to confirm miR-31-5p binding, shRNA knockdown, miRNA overexpression, AMPKα1 knockout, in vitro proliferation/apoptosis assays, in vivo xenograft tumor growth assay\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA pull-down confirms binding, loss-of-function with genetic rescue (AMPKα1 KO blocks effects), in vivo validation, single lab\",\n      \"pmids\": [\"30056111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MAGE-A3 overexpression facilitates cervical cancer cell proliferation, migration, and invasion by activating EMT markers and the Wnt signaling pathway; MAGE-A3 knockdown suppressed EMT and Wnt signaling and reduced in vivo tumor growth.\",\n      \"method\": \"qRT-PCR, loss-of-function (siRNA knockdown) and gain-of-function (overexpression) in HeLa and SiHa cells, Western blot for EMT and Wnt pathway proteins, in vivo tumorigenesis assay\",\n      \"journal\": \"Biomedicine & pharmacotherapy\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — Western blot for pathway markers is indirect; Wnt pathway activation not confirmed by direct Wnt reporter or target gene rescue; single lab, no rescue experiment\",\n      \"pmids\": [\"31918280\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MAGE-A3 expression in hepatocellular carcinoma is regulated by miR-31-5p; MAGEA3 depletion inhibited proliferation, invasion, and cisplatin resistance of HCC cells and reduced expression of drug resistance proteins MRP2, MRP3, and MDR-1; LINC01234 acts as a competing endogenous RNA to sponge miR-31-5p and thereby restore MAGEA3 expression.\",\n      \"method\": \"siRNA knockdown of MAGEA3, RNA pull-down and RIP assay for LINC01234/miR-31-5p/MAGEA3 binding, in vitro proliferation, invasion, and apoptosis assays, Western blot for MRP2, MRP3, MDR-1, ALB\",\n      \"journal\": \"Molecular therapy. Nucleic acids\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — mechanistic axis demonstrated by RIP/pull-down but rescue experiments use expression constructs without rigorous controls; single lab\",\n      \"pmids\": [\"31838274\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Receptor-mediated uptake of MAGE-A3 antigen by dendritic cells (via Fcγ receptor using antibody-opsonized protein, or via phagocytosis of bortezomib-treated apoptotic myeloma cells) favors cross-presentation and induction of CD8+ T cells, whereas macropinocytosis of uncoated protein preferentially induces CD4+ T cell priming.\",\n      \"method\": \"MAGE-A3 protein uptake assay with antibody opsonization, Fcγ receptor blocking, bortezomib-induced immunogenic apoptosis assay with hsp90 surface staining, phagocytosis assay, CD4+ and CD8+ T cell priming assays\",\n      \"journal\": \"Cancer immunology, immunotherapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor-specific uptake confirmed by blocking, functional T cell differentiation outcomes measured, single lab with orthogonal antigen delivery methods\",\n      \"pmids\": [\"22562379\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MAGEA3 encodes a ~48 kDa cytoplasmic cancer-germline protein that functions as a pro-survival factor in tumor cells (suppressing apoptosis at least partly by inhibiting AMPKα1 degradation and regulating Bax/p21/Puma/Noxa), whose promoter is epigenetically silenced in normal somatic tissues by DNA methylation and MBD1/MeCP2-mediated histone modifications but de-repressed in cancer through promoter demethylation and BORIS-driven chromatin remodeling; it presents multiple antigenic peptides via HLA class I (A1, A2, B44) and class II (DR1, DR11, DR13, DP4) molecules to cytolytic CD8+ and CD4+ T cells, with proteasomal processing of certain epitopes (e.g., MAGE-3271-279) being regulated by selective inhibition of specific proteasome activities.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MAGEA3 is a cancer-germline gene whose product is a ~48 kDa cytoplasmic protein that acts as a pro-survival factor in tumor cells while serving as a tumor-rejection antigen [#2, #16]. As an antigen, full-length MAGE-A3 protein is processed into multiple epitopes presented on HLA class I molecules — including HLA-A1, HLA-A2, and HLA-B44 — to cytolytic CD8+ T cells [#0, #1, #3], and into numerous promiscuous HLA class II epitopes (DR1, DR4/DR7, DR11, DR13, DP4) recognized by CD4+ T cells, several of which directly lyse antigen-positive tumor cells [#7, #8, #10, #13]. Presentation of certain class I epitopes is tuned at the proteasomal level: the HLA-A*0201-restricted MAGE-3271-279 peptide is poorly generated under normal conditions and its production is rescued by selective proteasome inhibition [#6], and class I deficiency in lung cancer cells abrogates CTL recognition until IFN-γ restores HLA and TAP expression [#5]. Because the protein is intracytoplasmic, dendritic cells acquire it by cross-presentation from apoptotic tumor bodies, with the uptake route (Fcγ-receptor versus macropinocytosis) biasing whether CD8+ or CD4+ responses are primed [#9, #22]. Functionally, MAGE-A3 supports tumor cell survival and chemoresistance: its knockdown induces apoptosis, modulates Bax/p21/Puma/Noxa, and sensitizes cells to chemotherapy [#16, #18], and it promotes proliferation in part by suppressing AMPKα1, since AMPKα1 knockout abolishes the anti-tumor effect of MAGE-A3 silencing [#19]. Expression is governed epigenetically — silenced in normal tissue by promoter methylation and methyl-CpG-binding proteins MBD1 and MeCP2, and by histone H3 methylation/acetylation balance — and de-repressed in cancer through BORIS-driven activating chromatin modifications and promoter demethylation [#14, #15, #17].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established MAGE-A3 as a bona fide tumor antigen by showing its product is recognized by autologous CTL, defining the first HLA-A1-restricted epitope and its binding anchor residues.\",\n      \"evidence\": \"Autologous CTL recognition and alanine-scanning peptide competition on melanoma cells\",\n      \"pmids\": [\"8113684\", \"7805731\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address how the epitope is generated intracellularly\", \"Restricted to HLA-A1 and HLA-A2 contexts initially\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Defined the physical product of the gene, showing MAGE-A3 is a ~48 kDa cytoplasmic protein.\",\n      \"evidence\": \"Monoclonal antibody immunoblot and immunohistochemistry on expressing cell lines\",\n      \"pmids\": [\"7757970\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No domain or biochemical activity assigned\", \"Single-lab antibody characterization\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Extended the antigenic repertoire to HLA-B44 and probed the antigen-processing pathway, linking TAP affinity to epitope availability.\",\n      \"evidence\": \"HLA-B44 refolding, CTL induction, and TAP binding assays\",\n      \"pmids\": [\"8606058\", \"8938145\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise trimming steps in the ER not defined\", \"TAP-binding model for the 11-mer remains a proposed mechanism\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Resolved why some epitopes escape recognition by showing proteasome activity gates generation of MAGE-3271-279, and broadened the picture to CD4+ T-cell recognition via multiple class II alleles.\",\n      \"evidence\": \"In vitro proteasome digestion with lactacystin and CTL assays; DC loading with recombinant protein and CD4+ T-cell clones (HLA-DR13, DR11)\",\n      \"pmids\": [\"10075973\", \"10049940\", \"10049951\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which specific proteasome subunit activities cleave the epitope not fully resolved\", \"Class II processing compartment not mapped\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrated how an intracytoplasmic antigen reaches T cells, establishing cross-presentation of MAGE-A3 from apoptotic tumor cells and adding HLA-DP4 class II presentation on tumor surfaces.\",\n      \"evidence\": \"DC phagocytosis of apoptotic bodies with CTL induction; CD4+ T-cell lysis of HLA-DP4+ tumor cells\",\n      \"pmids\": [\"10681453\", \"11103782\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating apoptotic body uptake not yet identified\", \"Efficiency of cross-presentation in vivo unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Systematically mapped naturally processed, promiscuous HLA-DR CD4+ epitopes, distinguishing processed from non-processed regions.\",\n      \"evidence\": \"TEPITOPE prediction, HLA-DR binding, and natural-processing confirmation with protein-loaded APCs\",\n      \"pmids\": [\"12393675\", \"11406551\", \"12817001\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab epitope mapping\", \"Cross-reactivity with other MAGE family members not exhaustively characterized\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Shifted the picture from antigen to functional driver by showing MAGE-A3 is required for tumor cell survival independent of proliferation or adhesion.\",\n      \"evidence\": \"siRNA knockdown in multiple myeloma lines with apoptosis, clonogenic, and chemosensitivity readouts\",\n      \"pmids\": [\"20015885\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular partners mediating survival not identified here\", \"Single tumor type\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined the epigenetic logic of MAGE-A3 silencing and de-repression, implicating promoter methylation, methyl-CpG-binding proteins, and histone-mark balance.\",\n      \"evidence\": \"ChIP, EMSA, methylation analysis, and luciferase reporters with MBD1/MeCP2 and FGF7/estradiol modulation\",\n      \"pmids\": [\"18381936\", \"17634428\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct demethylase machinery not identified\", \"In vivo relevance to tumor expression incompletely established\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified BORIS as a transcriptional activator that de-represses MAGEA3 in cancer via activating histone marks and promoter demethylation.\",\n      \"evidence\": \"ChIP, reporter assays, and BORIS gain/loss-of-function with methylation analysis in lung cancer cells\",\n      \"pmids\": [\"21558405\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of BORIS-induced demethylation unresolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Provided a molecular pro-survival mechanism, showing MAGE-A3/6 promote tumor growth by suppressing AMPKα1, with genetic rescue confirming the axis.\",\n      \"evidence\": \"shRNA/miR-1273g-3p silencing, AMPKα1 knockout rescue, and xenograft growth assays\",\n      \"pmids\": [\"30056111\", \"26868260\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biochemical link between MAGE-A3 and AMPKα1 degradation not reconstituted in these data\", \"Bax/p21/Puma/Noxa regulation correlative\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Connected MAGE-A3 to additional oncogenic pathways and non-coding RNA regulation in cervical and hepatocellular carcinoma.\",\n      \"evidence\": \"Gain/loss-of-function with EMT/Wnt marker blots; miR-31-5p/LINC01234 ceRNA axis with RIP and drug-resistance protein analysis\",\n      \"pmids\": [\"31918280\", \"31838274\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Wnt activation shown only by marker blots without reporter or rescue\", \"ceRNA rescue lacks rigorous controls; single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the cytoplasmic MAGE-A3 protein biochemically engages AMPKα1, the apoptotic machinery, and its degradation pathway to mediate tumor cell survival remains undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct binding partner or structural model for the survival function\", \"Mechanism linking antigen-processing biology to oncogenic function unexplored\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [19, 16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 3, 7, 8, 10]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [16, 18, 19]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [14, 15, 17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"AMPKα1\", \"MBD1\", \"MeCP2\", \"BORIS\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}